- Reaction score
- 1,697
A new Alzheimer’s therapy has shown potential in the first human trials.
Researchers at the West Virginia University Rockefeller Neuroscience Institute (RNI) found that by pairing focused ultrasound in combination with antibody therapies, they were able to accelerate the removal of amyloid-beta plaques from the brains of patients with Alzheimer’s disease.
The study findings were published in The New England Journal of Medicine on Jan. 11.
An abnormal buildup of amyloid-beta proteins is one of the hallmarks of Alzheimer’s, as these proteins clump together to form plaques that interfere with neurons in the brain.
Anti-amyloid-beta monoclonal antibody treatments, such as aducanumab and lecanemab, have proven to be effective in clearing these plaques and slowing disease progression.
news.yahoo.com
Researchers at the West Virginia University Rockefeller Neuroscience Institute (RNI) found that by pairing focused ultrasound in combination with antibody therapies, they were able to accelerate the removal of amyloid-beta plaques from the brains of patients with Alzheimer’s disease.
The study findings were published in The New England Journal of Medicine on Jan. 11.
An abnormal buildup of amyloid-beta proteins is one of the hallmarks of Alzheimer’s, as these proteins clump together to form plaques that interfere with neurons in the brain.
Anti-amyloid-beta monoclonal antibody treatments, such as aducanumab and lecanemab, have proven to be effective in clearing these plaques and slowing disease progression.
New Alzheimer’s treatment accelerates removal of plaque from the brain in clinical trials
By pairing focused ultrasound in combination with antibody therapies, researchers were able to accelerate the removal of amyloid-beta plaques from the brains of patients with Alzheimer’s disease.
